BRPI0415356A - derivados bicìclicos [3.1.0] como inibidores do transportador de glicina - Google Patents

derivados bicìclicos [3.1.0] como inibidores do transportador de glicina

Info

Publication number
BRPI0415356A
BRPI0415356A BRPI0415356-1A BRPI0415356A BRPI0415356A BR PI0415356 A BRPI0415356 A BR PI0415356A BR PI0415356 A BRPI0415356 A BR PI0415356A BR PI0415356 A BRPI0415356 A BR PI0415356A
Authority
BR
Brazil
Prior art keywords
transporter inhibitors
glycine transporter
bicyclic derivatives
formula
derivatives
Prior art date
Application number
BRPI0415356-1A
Other languages
English (en)
Inventor
John A Lowe
Stan Mchardy
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34465157&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0415356(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0415356A publication Critical patent/BRPI0415356A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"DERIVADOS BICìCLICOS ¢3.1.0! COMO INIBIDORES DO TRANSPORTADOR DE GLICINA". A presente invenção relaciona-se com uma série de aminas bicíclicas ¢3.1.0! substituídas de fórmula I: Fórmula I em que A, B, D, Q, V, W, X, Y, Z, R¬ 2¬, R¬ 3¬, R¬ 4¬, R¬ 5¬, R¬ 14¬, R¬ 15¬, R¬ 30¬, o, p, s, t e q são como definidos na especificação, os seu sais farmaceuticamente aceitáveis, as suas composições, e a sua utilização para aumento da cognição e o tratamento dos sintomas positivos e negativos de esquizofrenia e outras psicoses em mamíferos, incluindo seres humanos.
BRPI0415356-1A 2003-10-14 2004-10-14 derivados bicìclicos [3.1.0] como inibidores do transportador de glicina BRPI0415356A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51084603P 2003-10-14 2003-10-14
PCT/US2004/034083 WO2005037216A2 (en) 2003-10-14 2004-10-14 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors

Publications (1)

Publication Number Publication Date
BRPI0415356A true BRPI0415356A (pt) 2006-12-12

Family

ID=34465157

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415356-1A BRPI0415356A (pt) 2003-10-14 2004-10-14 derivados bicìclicos [3.1.0] como inibidores do transportador de glicina

Country Status (26)

Country Link
US (1) US7473787B2 (pt)
EP (1) EP1680124B1 (pt)
JP (2) JP4732354B2 (pt)
KR (1) KR20060095865A (pt)
CN (2) CN101838271A (pt)
AP (1) AP2006003592A0 (pt)
AU (1) AU2004281794B2 (pt)
BR (1) BRPI0415356A (pt)
CA (1) CA2542279C (pt)
CR (2) CR8333A (pt)
DK (1) DK1680124T3 (pt)
EA (1) EA009903B1 (pt)
EC (1) ECSP066504A (pt)
ES (1) ES2634841T3 (pt)
GE (1) GEP20104959B (pt)
IL (1) IL174299A (pt)
IS (1) IS8355A (pt)
MA (1) MA28094A1 (pt)
MX (1) MXPA06004279A (pt)
NO (1) NO337361B1 (pt)
NZ (1) NZ546012A (pt)
RS (1) RS20060190A (pt)
TN (1) TNSN06109A1 (pt)
UA (1) UA86037C2 (pt)
WO (1) WO2005037216A2 (pt)
ZA (1) ZA200602174B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA009903B1 (ru) * 2003-10-14 2008-04-28 Пфайзер Продактс Инк. Бициклические [3.1.0] производные в качестве ингибиторов переносчиков глицина
GB0408774D0 (en) * 2004-04-20 2004-05-26 Glaxo Group Ltd Compounds
GB0408772D0 (en) * 2004-04-20 2004-05-26 Glaxo Group Ltd Compounds
WO2006002133A1 (en) * 2004-06-22 2006-01-05 Schering Corporation Cannabinoid receptor ligands
MX2007012463A (es) * 2005-04-08 2007-11-07 Pfizer Prod Inc Heteroarilamidas[3.1.0]biciclicas como inhibidores del transporte de glicina de tipo i.
US8067415B2 (en) 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
US8067457B2 (en) 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
WO2007135527A2 (en) * 2006-05-23 2007-11-29 Pfizer Products Inc. Benzimidazolyl compounds
WO2008065500A2 (en) * 2006-11-30 2008-06-05 Pfizer Products Inc. Heteroaryl amides as type i glycine transport inhibitors
MX2010004815A (es) * 2007-11-05 2010-05-27 Merck Patent Gmbh Derivados de 7-azaindol como inhibidores selectivos de la 11-beta-hidroxiesteroide deshidrogenasa de tipo 1.
MX2011006169A (es) * 2008-12-12 2011-06-27 Univ Vanderbilt Inhibidores 3.3.0-biciclicos de giyt1 y metodos para hacer y utilizar los mismos.
EP2381941A4 (en) * 2008-12-29 2012-08-01 Univ Vanderbilt 3.1.0 BICYCLIC GLYTI INHIBITORS AND METHOD FOR THE PRODUCTION AND USE THEREOF
FR2944283B1 (fr) * 2009-04-14 2011-05-06 Sanofi Aventis Derives de n-°(2-aza-bicyclo°2.1.1!hex-1-yl)-aryl-methyl!- heterobenzamide, leur preparation et leur application en therapeutique
US8623898B2 (en) 2009-03-19 2014-01-07 Taisho Pharmaceutical Co., Ltd. Glycine transporter inhibiting substances
EP2617715A4 (en) 2010-09-17 2014-02-26 Taisho Pharmaceutical Co Ltd GLYCINTRANSPORTERHEMMER
BR112013007566A2 (pt) 2010-09-28 2016-08-02 Panacea Biotec Ltd novos compostos bicíclicos
US9012489B2 (en) * 2011-08-03 2015-04-21 Boehringer Ingelheim International Gmbh Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament
US9371282B2 (en) 2013-05-17 2016-06-21 Centrexion Therapeutics Corporation Somatostatin receptor subtype 4 (SSTR4) agonists
CN103319645B (zh) * 2013-05-31 2016-08-10 南京洁雅新材料有限公司 一种水性金属保护剂及其生产工艺
JP6581111B2 (ja) * 2014-04-28 2019-09-25 メッドシャイン ディスカバリー インコーポレイテッド Ｒｈｏキナーゼ阻害剤としてのイソキノリンスルホン誘導体
US10626081B2 (en) 2015-09-16 2020-04-21 Metacrine, Inc. Farnesoid X receptor agonists and uses thereof
EP3350165B1 (en) 2015-09-16 2023-07-26 Organovo, Inc. Farnesoid x receptor agonists and uses thereof
WO2017049176A1 (en) * 2015-09-16 2017-03-23 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
EP3350166A4 (en) 2015-09-16 2019-05-01 Metacrine, Inc. FARNESOID-X RECEPTOR AGONISTS AND USES THEREOF
CR20210545A (es) * 2019-05-01 2021-12-23 Boehringer Ingelheim Int Formas sólidas de un inhibidor de glyt1
BR112021024108A2 (pt) 2019-05-31 2022-03-22 Ikena Oncology Inc Inibidores de tead e usos dos mesmos
US11458149B1 (en) 2019-05-31 2022-10-04 Ikena Oncology, Inc. TEAD inhibitors and uses thereof
CA3188340A1 (en) 2020-08-13 2022-02-17 Boehringer Ingelheim International Gmbh Treatment of cognitive impairement associated with schizophrenia
KR20230088761A (ko) 2020-10-13 2023-06-20 베링거 인겔하임 인터내셔날 게엠베하 재가공하는 방법
TWI860849B (zh) 2021-09-14 2024-11-01 美商美國禮來大藥廠 Sstr4促效劑鹽
CN119039274A (zh) * 2023-05-29 2024-11-29 武汉熙瑞医药科技有限公司 3-氮杂-双环[3.1.0]己烷衍生物、其制备方法及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ326874A (en) * 1996-03-29 2000-01-28 Pfizer 6-phenylpyridyl-2-amine derivatives
AU730789B2 (en) * 1996-05-31 2001-03-15 Nps Pharmaceuticals, Inc. Pharmaceutical for treatment of neurological and neuropsychiatric disorders
ES2248633T3 (es) * 2001-04-17 2006-03-16 MERCK & CO., INC. Antibioticos oxazolidinona que contienen biciclo (3,1,o)hexano y derivados de los mismos.
JP4155522B2 (ja) * 2001-10-22 2008-09-24 ファイザー・プロダクツ・インク オピオイド受容体アンタゴニストとしての３−アザビシクロ（３．１．０）ヘキサン誘導体
WO2003037865A1 (en) 2001-10-31 2003-05-08 Morphochem Aktiengesellschaft für kombinatorische Chemie Novel anticancer compounds
GB0130696D0 (en) * 2001-12-21 2002-02-06 Smithkline Beecham Plc Chemical Compounds
EA200500173A1 (ru) * 2002-07-08 2005-08-25 Рэнбакси Лабораториз Лимитед Производные 3,6-дизамещенного азабицикло[3.1.0]гексана в качестве антагонистов мускариновых рецепторов
EP1534675B1 (en) * 2002-08-23 2009-02-25 Ranbaxy Laboratories, Ltd. Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo¬3.1.0 hexane derivatives as muscarinic receptor antagonists
WO2004089900A1 (en) * 2003-04-11 2004-10-21 Ranbaxy Laboratories Limited Azabicyclo derivatives as muscarinic receptor antagonists
EA009903B1 (ru) * 2003-10-14 2008-04-28 Пфайзер Продактс Инк. Бициклические [3.1.0] производные в качестве ингибиторов переносчиков глицина
AU2004281229A1 (en) * 2003-10-16 2005-04-28 Pfizer Products Inc. Preparation of 3-azabicyclo (3.1.0) hexane derivatives
NZ552298A (en) 2004-05-23 2011-04-29 Gerard M Housey Method for identifying inhibitors or activators of a theramutein by comparing the phenoresponse of cells exposed to a test compound

Also Published As

Publication number Publication date
ES2634841T3 (es) 2017-09-29
US20050096375A1 (en) 2005-05-05
IL174299A (en) 2011-12-29
IL174299A0 (en) 2006-08-01
AU2004281794A1 (en) 2005-04-28
RS20060190A (sr) 2008-08-07
CA2542279A1 (en) 2005-04-28
WO2005037216A3 (en) 2005-08-04
CR20110095A (es) 2011-03-09
NZ546012A (en) 2009-12-24
JP2011157358A (ja) 2011-08-18
CN101838271A (zh) 2010-09-22
EA200600513A1 (ru) 2006-08-25
AU2004281794B2 (en) 2010-04-22
IS8355A (is) 2006-03-16
NO20062193L (no) 2006-05-15
JP2007508374A (ja) 2007-04-05
CR8333A (es) 2007-08-14
TNSN06109A1 (fr) 2007-11-15
WO2005037216A2 (en) 2005-04-28
ZA200602174B (en) 2007-04-25
NO337361B1 (no) 2016-03-29
EP1680124A2 (en) 2006-07-19
DK1680124T3 (en) 2017-08-21
ECSP066504A (es) 2006-10-10
JP4732354B2 (ja) 2011-07-27
GEP20104959B (en) 2010-04-26
EA009903B1 (ru) 2008-04-28
EP1680124B1 (en) 2017-05-31
EP1680124A4 (en) 2009-05-13
CN1867338A (zh) 2006-11-22
CA2542279C (en) 2011-08-09
UA86037C2 (ru) 2009-03-25
MXPA06004279A (es) 2006-06-28
KR20060095865A (ko) 2006-09-04
MA28094A1 (fr) 2006-08-01
US7473787B2 (en) 2009-01-06
AP2006003592A0 (en) 2006-04-30

Similar Documents

Publication Publication Date Title
UA86037C2 (ru) Бициклические [3.1.0] производные, как ингибиторы переносчика глицина
BRPI0608148A2 (pt) [3.1.01] heteroaril amidas bicìclicas como inibidores de transporte de glicina do tipo i,composição farmacêutica para tratamento de distúrbio e seu uso
BRPI0416692A (pt) inibidores heterocìclicos de mek e métodos de emprego destes
BR122018007328B8 (pt) composto, composição farmaceutica e uso do dito composto
BRPI0513864A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, sua utilização e método para o tratamento e/ou profilaxia de enfermidades
BR0316081A (pt) Derivados de 2-piridona como inibidores de elastase de neutrófilo
BRPI0617167B8 (pt) sulfonilpirróis como inibidores de hdac's, seu uso, composição farmacêutica e combinação
BRPI0413152A (pt) derivados de benzimidazol alquilado por n3 como inibidores de mek
BRPI0515931A (pt) compostos, processo para a sua preparação, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades e utilização desses compostos
BR0009044A (pt) Composto, composição farmacêutica, método para tratar uma doença em um animal, uso de um composto, e, processo para fabricar um composto
BR0314393A (pt) Piperazinas heterocìclicas substituìdas para o tratamento de esquizofrenia
BR0313160A (pt) Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto
BRPI0414111A (pt) inibidores heterocìclicos de mek e métodos de uso dos mesmos
BRPI0606313A2 (pt) derivados de 4-(1h-indol-3-il)-pirimidin-2-ilamina, processo para sua preparação e seu uso em terapia
NO20075270L (no) Antibakterielle amid-makrocykler V
BR0203274A (pt) teres aromáticos de difluorometilenos
BRPI0411092A (pt) benzo[b]tiofenos substituìdos com 3-arilsulfanila e com 3-heteroarilsulfanila como agentes terapêuticos
MXPA03011596A (es) Eteres aromaticos sustituidos utilizados como inhibidores del transporte de la glicina.
BR0313278A (pt) Compostos, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo e sua utilização, método para o tratamento e profilaxia de enfermidades e obesidade e utilização dos compostos
ECSP099506A (es) Derivados de 2-quinolinona y 2 quinoxalinona y su utilización como agentes anti bacterianos
BR0314796A (pt) Piperazinas substituìdas heterocìclicas para o tratamento de esquizofrenia
BRPI0510032A (pt) tiofeno heteroaril aminas
DOP2001000189A (es) Benzofenonas y sulfonas como inhibidores de la captación de glicina
BR0308807A (pt) Compostos tiazol-2-il-imina como inibidores de pde-7
BR0306861A (pt) Combinações que compreendem epotilonas e antimetabólitos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/5375; C07D 413/12; A61P 25/148

Ipc: A61K 31/5375 (2011.01), C07D 413/12 (2011.01), A61

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.